<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03086382</url>
  </required_header>
  <id_info>
    <org_study_id>SP1001</org_study_id>
    <nct_id>NCT03086382</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects</brief_title>
  <official_title>A Randomized, Open-Label, Single-Dose, 2-Period Crossover Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate bioequivalence between the LCM tablet and syrup
      after single oral dosing in healthy Chinese male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Actual">March 28, 2017</completion_date>
  <primary_completion_date type="Actual">March 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of Lacosamide (LCM)</measure>
    <time_frame>Blood samples are collected at predose and 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours after dosing</time_frame>
    <description>Blood samples will be taken at indicated time points to determine maximum Lacosamide (LCM) plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the LCM plasma concentration-time curve from time zero up to the time of last quantifiable concentration (AUC[0-t])</measure>
    <time_frame>Blood samples are collected at predose and 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours after dosing</time_frame>
    <description>Area under the LCM plasma concentration-time curve from time zero up to the last quantifiable concentration data point, computed using the log-linear trapezoidal rule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the LCM plasma concentration-time curve extrapolated to infinity (AUC)</measure>
    <time_frame>Blood samples are collected at predose and 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours after dosing</time_frame>
    <description>Area under the LCM plasma concentration-time curve extrapolated to infinity calculated as AUC(0-t) + t/z, where t is the estimated plasma concentration at time t and z the terminal elimination rate constant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal plasma elimination half-life (t1/2) of LCM</measure>
    <time_frame>Blood samples are collected at predose and 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours after dosing</time_frame>
    <description>Terminal elimination half-life of LCM, reported in hours, as determined via simple linear regression(slope=-z) of natural log (ln) concentration vs time for data points in the terminal phase of the concentration-time curve. tÂ½ is calculated as ln(2)/z.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of observed Cmax (tmax) of LCM</measure>
    <time_frame>Blood samples are collected at predose and 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours after dosing</time_frame>
    <description>Time of observed Cmax will be obtained directly from the plasma concentration-time curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent plasma clearance (CL/F) of LCM</measure>
    <time_frame>Blood samples are collected at predose and 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours after dosing</time_frame>
    <description>Apparent plasma clearance calculated as CL/F=Dose/AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of LCM</measure>
    <time_frame>Blood samples are collected at predose and 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours after dosing</time_frame>
    <description>Apparent volume of distribution, calculated as Vz/F=(CL/F)/z.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment A - B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B - A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg) under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide (LCM) tablet</intervention_name>
    <description>Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg</description>
    <arm_group_label>Treatment A - B</arm_group_label>
    <arm_group_label>Treatment B - A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide (LCM) syrup</intervention_name>
    <description>Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup</description>
    <arm_group_label>Treatment A - B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a Chinese male between 18 and 40 years of age

          -  Subject has no clinically significant cardiovascular, renal, gastrointestinal,
             hepatic, metabolic, endocrine, neurological, or psychiatric abnormalities and is in
             general good health

          -  Subject confirms that during the study and for a period of 3 months after the final
             dose of study drug, when having sexual intercourse with a woman of childbearing
             potential, an acceptable birth control method will be used

        Exclusion Criteria:

        Clinically significant

          -  out of range values for hematology and clinical chemistry variables

          -  abnormality in physical examination or vital signs

          -  ECG finding Any clinical conditions that in the opinion of the investigator would make
             the subject unsuitable for the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>UCB (+1 877 822 9493)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sp1001 001</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lacosamide</keyword>
  <keyword>Syrup</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Tablet</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

